OptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $9.06.

OPRX has been the topic of a number of recent research reports. JMP Securities reaffirmed a "market outperform" rating and issued a $8.00 price objective on shares of OptimizeRx in a research note on Thursday, February 6th. B. Riley upgraded shares of OptimizeRx to a "strong-buy" rating in a research note on Wednesday, March 12th.

OptimizeRx Stock Down 5.2%

NASDAQ:OPRX traded down $0.52 during trading hours on Thursday, reaching $9.47. The company had a trading volume of 201,979 shares, compared to its average volume of 269,228. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a market cap of $175.17 million, a price-to-earnings ratio of -7.08 and a beta of 1.28. The business's 50-day simple moving average is $8.14 and its two-hundred day simple moving average is $6.31. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $14.13.

Insider Activity

In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of OptimizeRx stock in a transaction that occurred on Friday, March 14th. The shares were bought at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares of the company's stock, valued at approximately $2,959,835.20. This trade represents a 472.35% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On OptimizeRx

Several large investors have recently bought and sold shares of OPRX. GAMMA Investing LLC purchased a new position in OptimizeRx during the first quarter worth $33,000. SBI Securities Co. Ltd. purchased a new stake in shares of OptimizeRx during the fourth quarter valued at $25,000. SG Americas Securities LLC purchased a new stake in shares of OptimizeRx during the fourth quarter valued at $51,000. Wells Fargo & Company MN boosted its stake in shares of OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares during the period. Finally, Graham Capital Management L.P. purchased a new stake in shares of OptimizeRx during the fourth quarter valued at $81,000. Institutional investors own 76.47% of the company's stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.